New endpoints for early-stage cancer are gaining regulatory traction

Using the standard regulatory endpoints of overall survival (OS) and progression-free survival (PFS) may not be feasible in some early-stage cancer trials due to the time it would take to reach the number of patient deaths and disease progression events to demonstrate efficacy. Novel endpoints that can offer quicker insights into the short- or long-term clinical benefits of new cancer drugs are needed, especially for early-stage cancer and immediately before (neoadjuvant) and after (adjuvant) primary treatment. This article covers three promising new endpoints.

Open PDF

Return to Insights Center

Related Insights


Q&A Project Optimus: What you need to know

Oct 11, 2022


Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022


The Potential of Neoadjuvant Therapy in the Treatment of Solid Tumors

Apr 15, 2024


EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022


Parexel names first Patient Ambassador

Jun 17, 2022


8 things you need to know about eCTDs in China

Jul 1, 2022


Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022


What Do the Next 10 Years Hold for CRISPR?

Jul 27, 2022


Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022